OCC - Orthocell Limited

Orthocell Limited (OCC) appears to be threatening for a breakout to the upside and, as such, is a personal stock selection for the February stock competition here at ASF. Referring to the daily chart below, we have the share price closing above the 10 and 30 day MA's at the end of the final complete trading week of the January calendar month, whilst also closing above two recent opens which could potentially act as support/resistance areas from 6th January and 10th January ($1.53 and $1.495, respectively). A supportive DMI/ADX and RSI also assist a potentially bullish perspective from a technical analysis aspect.

Price continuing to hold strongly after rise to $1.50 in late Deceember '24.

Recent approval for Remplir in Singapore should pass on in the next few months to Thailand who recognize each others approvals. Both these countries are destination countries for medical procedures from people throughout South East Asia.

Then we wait for Remplir approval in America by mid-year.

access said:

Price continuing to hold strongly after rise to $1.50 in late Deceember '24.

Recent approval for Remplir in Singapore should pass on in the next few months to Thailand who recognize each others approvals. Both these countries are destination countries for medical procedures from people throughout South East Asia.

Then we wait for Remplir approval in America by mid-year.

Click to expand...

Closed at a record high today.